Chemotherapy News and Research

Latest Chemotherapy News and Research

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Patients with advanced lung adenocarcinoma who produce the XAGE1 antibody appear to survive twice as long as those who do not produce it, Japanese study data show.

24 Sep 2014

Novel treatment makes life-saving difference to young patients with Ph-like ALL

St. Jude Children's Research Hospital investigators found that adjusting treatment based on early response to chemotherapy made a life-saving difference to young patients with an acute lymphoblastic leukemia (ALL) subtype associated with a poor outcome.

24 Sep 2014

Rice University research yields new two-step strategy for weakening cancer

Research by Rice University scientists who are fighting a cyberwar against cancer finds that the immune system may be a clinician's most powerful ally.

24 Sep 2014

Distinct patterns of gene expression identified in several groups of pancreatic CTCs

Analysis of circulating tumor cells (CTCs) in a mouse model of pancreatic cancer identified distinct patterns of gene expression in several groups of CTCs, including significant differences from the primary tumor that may contribute to the ability to generate metastases.

23 Sep 2014

Researchers develop protein therapy that may stop cancer growth

A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.

22 Sep 2014

Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

In anticipation of next year's premium announcements and given some information already made public, concerns have surfaced about the potential for double-digit percent increases in nongroup and small-group health insurance premiums. This analysis shows that, although average annual increases in small-group premiums over the past 13 years averaged roughly 5.5 percent, double-digit average premium increases are common for states and large metropolitan areas.

22 Sep 2014

Sequencing the Asian liver fluke genome: an interview with Dr Neil Young

Opisthorchis viverrini is a parasitic flatworm (or liver fluke) endemic throughout Thailand, the Lao People’s Democratic Republic, Vietnam and Cambodia. Humans are infected with this parasite when they eat a fluke encysted in inadequately cooked/preserved freshwater fish.

21 Sep 2014

Longer looks: Lithium in the water; controlling cancer; recovering from brain injury

There are many kinds of cancer, but treatments have typically combatted them in one way only: by attempting to destroy the cancerous cells. Surgery aims to remove the entire growth from the body; chemotherapy drugs are toxic to the cancer cells; radiation generates toxic molecules that break up the cancer cells' DNA and proteins, causing their demise.

19 Sep 2014

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Study after study has proven it true: exercise is good for you. But new research from University of Pennsylvania scientists suggests that exercise may have an added benefit for cancer patients undergoing chemotherapy.

19 Sep 2014

State highlights: Report: Hospitals ill-prepared for Sandy; Iowa Supreme Court lets teleabortion go on while it decides

When Superstorm Sandy slammed into the Northeast nearly two years ago, hospitals found themselves dealing with surges in patients, lost power supplies and employees who couldn't get to work -- problems that a new federal report finds they were not prepared to handle (Mulvihill, 9/17).

18 Sep 2014

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC).

18 Sep 2014

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial.

17 Sep 2014

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Combining erlotinib with bevacizumab could prolong progression-free survival in patients being treated for epidermal growth factor receptor-mutated non-small-cell lung cancer, phase II trial results suggest.

17 Sep 2014

S. pneumoniae drug susceptibility tracked in Japan

A 12-year survey of the antimicrobial susceptibility of Streptococcus pneumoniae isolates in Miyagi Prefecture in Japan has identified important changes, including improved susceptibility to β-lactam antibiotics.

17 Sep 2014

S-1 plus radiotherapy shows promise in elderly NSCLC patients

Concurrent administration of S-1 chemotherapy and radiotherapy has a favourable impact on survival in elderly patients with locally advanced non-small-cell lung cancer, a phase II trial has found.

17 Sep 2014

ICO-IDIBELL researchers identify 5 genes differentially expressed in colorectal tumors

Researchers at the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute, led by David Garcia-Mollev- have identified 5 genes differentially expressed in normal accompanying cells in colorectal tumors.

17 Sep 2014

Current smokers at increased risk of developing SPLC

Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

17 Sep 2014

Novel genetic discovery identifies new avenues for prostate cancer treatment

A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment.

17 Sep 2014

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I).

17 Sep 2014

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma (ESCC), according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

16 Sep 2014

Chemotherapy News and Research

Latest Chemotherapy News and Research

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Novel treatment makes life-saving difference to young patients with Ph-like ALL

Rice University research yields new two-step strategy for weakening cancer

Distinct patterns of gene expression identified in several groups of pancreatic CTCs

Researchers develop protein therapy that may stop cancer growth

Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

Sequencing the Asian liver fluke genome: an interview with Dr Neil Young

Longer looks: Lithium in the water; controlling cancer; recovering from brain injury

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

State highlights: Report: Hospitals ill-prepared for Sandy; Iowa Supreme Court lets teleabortion go on while it decides

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Ramucirumab effective second-line option for NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

S. pneumoniae drug susceptibility tracked in Japan

S-1 plus radiotherapy shows promise in elderly NSCLC patients

ICO-IDIBELL researchers identify 5 genes differentially expressed in colorectal tumors

Current smokers at increased risk of developing SPLC

Novel genetic discovery identifies new avenues for prostate cancer treatment

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in